NCT03423758 Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma
| NCT ID | NCT03423758 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Vienna |
| Condition | Glaucoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2017-05-30 |
| Primary Completion | 2026-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2017-05-30 with a primary completion date of 2026-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There is increasing evidence that there are genetic risk factors for several forms of glaucoma, such as glaucoma caused by pseudoexfoliation syndrome (PXF) ,primary angle closure glaucoma (PACG) and primary open-angle glaucoma (POAG). The aim of the present prospective, multi-center, case-control study is to identify susceptibility genes/loci for PXF, PACG and POAG using a whole genome association (WGA) approach.
Eligibility Criteria
Inclusion Criteria: 1. For patients with PXF: * Patients with confirmed pseudoexfoliation syndrome (exfoliation glaucoma / pseudoexfoliation of the lens) in the medical history * Informed consent * Age 50 years or more 2. For patients with PACG: * Patients with confirmed acute primary angle closure (PAC) or primary angle closure glaucoma (PACG) in the medical history * Informed consent * Age 21 years or more 3. For healthy controls: * No evidence of PXF, glaucoma or uveitis during clinical examination or in the medical history * No evidence of major ocular disease such as diabetic retinopathy, age related macular degeneration or conditions with genetic background during clinical examination or in the medical history * Age more than 60 years * Informed consent 4. For patients with POAG: * Patients with confirmed primary open angle glaucoma (POAG) * No evidence of exfoliation glaucoma / pseudoexfoliation of the lens or pigment glaucoma * Informed consent * Age 30 or more Exclusion Criteria: * Patients and subjects will be excluded if one or more of the following criteria apply: * Neovascular glaucoma * Active or history of uveitis * Secondary angle closure such as neovascular glaucoma or uveitis/inflammatory eye disease * Inability to give informed consent
Contact & Investigator
Gerhard Garhöfer
PRINCIPAL INVESTIGATOR
Medical University of Vienna
Frequently Asked Questions
Who can join the NCT03423758 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 105 Years, studying Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03423758 currently recruiting?
Yes, NCT03423758 is actively recruiting participants. Contact the research team at gerhard.garhoefer@meduniwien.ac.at for enrollment information.
Where is the NCT03423758 trial being conducted?
This trial is being conducted at Vienna, Austria.
Who is sponsoring the NCT03423758 clinical trial?
NCT03423758 is sponsored by Medical University of Vienna. The principal investigator is Gerhard Garhöfer at Medical University of Vienna. The trial plans to enroll 300 participants.